NASDAQ:BGNEBeigene Stock Price, Forecast & News

Beigene's stock was trading at $145.69 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BGNE stock has increased by 54.2% and is now trading at $224.64.
View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Beigene.

Beigene is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Beigene.

Beigene Ltd (NASDAQ:BGNE) released its quarterly earnings results on Monday, May, 11th. The company reported ($4.70) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($4.85) by $0.15. The business earned $52.06 million during the quarter, compared to analysts' expectations of $27 million. Beigene had a negative net margin of 284.45% and a negative return on equity of 68.64%.
View Beigene's earnings history.

11 brokerages have issued 12-month price targets for Beigene's stock. Their forecasts range from $165.00 to $250.00. On average, they expect Beigene's share price to reach $214.48 in the next year. This suggests that the stock has a possible downside of 4.5%.
View analysts' price targets for Beigene.

Media coverage about BGNE stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Beigene earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term.
View the latest news about Beigene.

Some companies that are related to Beigene include Celgene (CELG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Bayer (BAYRY), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), UCB (UCBJF), Genmab A/S (GMAB), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), BioMarin Pharmaceutical (BMRN) and Genmab A/S (GNMSF).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Beigene investors own include NVIDIA (NVDA), Alibaba Group (BABA), Crispr Therapeutics (CRSP), Square (SQ), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Intuitive Surgical (ISRG), InVitae (NVTA), AbbVie (ABBV) and JD.Com (JD).

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

Beigene's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Matthews International Capital Management LLC (0.32%), Sumitomo Mitsui Trust Holdings Inc. (0.22%), Candriam Luxembourg S.C.A. (0.21%), Swiss National Bank (0.17%), Russell Investments Group Ltd. (0.06%) and MERIAN GLOBAL INVESTORS UK Ltd (0.07%). Company insiders that own Beigene stock include Amy C Peterson, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends for Beigene.

BGNE stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Matthews International Capital Management LLC, DekaBank Deutsche Girozentrale, Sumitomo Mitsui Trust Holdings Inc., Vident Investment Advisory LLC, Vident Investment Advisory LLC, Mckinley Capital Management LLC Delaware, and Profund Advisors LLC. Company insiders that have sold Beigene company stock in the last year include Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu, and Xiaodong Wang.
View insider buying and selling activity for Beigene.

BGNE stock was acquired by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Candriam Luxembourg S.C.A., M&G Investment Management Ltd., Swiss National Bank, ProShare Advisors LLC, First Quadrant L P CA, Dupont Capital Management Corp, and SG Americas Securities LLC.
View insider buying and selling activity for Beigene.

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BGNE stock can currently be purchased for approximately $224.64.

Beigene has a market capitalization of $20.07 billion and generates $428.21 million in revenue each year. The company earns $-948,630,000.00 in net income (profit) each year or ($15.80) on an earnings per share basis. Beigene employs 3,500 workers across the globe.

The official website for Beigene is www.beigene.com.

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]